Paradigm Shift in Inflammatory Bowel Disease Management—Advanced Therapy Utilisation, Persistence, and Outcomes in a United Arab Emirates Cohort During 2015–2025
Clicks: 1
ID: 317494
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #5 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background The therapeutic landscape for inflammatory bowel disease (IBD) has expanded rapidly beyond anti-TNF agents. We characterised the evolution of advanced therapy utilisation, persistence, and outcomes in a United Arab Emirates (UAE) cohort during 2015-2025. Methods This prospective registry study from a tertiary IBD facility in the UAE included 508 patients (333 Crohn’s disease [CD], 175 ulcerative colitis [UC]). Advanced therapies were grouped by mechanism of action. We compared prescribing patterns between 'Pre-2023' and '2023 and Beyond’ eras. Treatment persistence was analysed using Kaplan-Meier methods and Cox proportional hazards models. Results Of 508 patients, 380 (74.8%) received advanced therapy. In CD, first-line anti-TNF use fell from 76% (pre-2023) to 42% (2023+), with anti-IL-23 agents emerging as a major first-line option (32%). Median time to first advanced therapy decreased dramatically: CD from 23.0 to 2.0 months (p < 0.0001) and UC from 37.0 to 3.0 months (p < 0.0001). Anti-IL-23 agents demonstrated significantly superior persistence in CD first-line therapy (p = 0.011 vs anti-TNF). In multivariable analysis, anti-IL-23 therapy was associated with significantly lower discontinuation risk (HR: 0.35, 95% CI: 0.19-0.64, p = 0.0008). Infliximab persistence appeared to improve over time, with significantly better 1-year persistence in 2024+ versus 2018-2019 (pairwise p = 0.020; overall trend p = 0.05). A shift in UC second-line prescribing was also observed (p = 0.048). Early surgery rates were low across both eras (CD: 6.5% vs 3.9%; UC: 2.5% vs 1.9%) with no significant difference in 35-month surgery-free survival, though this analysis was underpowered. Conclusions IBD management in the UAE has undergone a rapid paradigm shift since 2023, characterised by earlier therapy initiation and diversification away from anti-TNF dominance, particularly in CD. Superior persistence of anti-IL-23 agents in our cohort is consistent with this evolution in clinical practice and supports its further evaluation.
| Reference Key |
openalex_W7164884656
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | H A Ahmed, Mohamed Nasir Alzaabi, Thaer Khaleel Swai, Shaima Khan, Maitha Al Hosani, Noura Al Hosani, Maryam AlAhmad, N M Omar, Esraa Ahmed, Ishtiaq Ahmed, Kishor Kumar, Laurette L Bukasa, Tine Jess, Mohammed Nabil Quraishi |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag057
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.